Internal Medicine and Hepatology Unit, Department of Medicine, Surgery and Dentistry, Scuola Medica Salernitana, University of Salerno, Largo Città d'Ippocrate, 84131 Salerno, Italy.
Viruses. 2023 Oct 31;15(11):2199. doi: 10.3390/v15112199.
HCV infection is still a major burden worldwide, and most countries are not on track to meet the WHO 2030 elimination goal. The current challenge is to identify individuals to be treated. In this study, we will describe the trend of new DAA prescriptions and the changes over time in terms of the characteristics of patients starting antiviral therapy in our unit. Data of 1646 hepatitis C patients who started therapy during the period of 2015-2022 regarding annual number of prescriptions, age, gender, nationality, HCV genotype, provenance, and liver disease severity were analyzed. We observed a peak in the number of new prescriptions in 2018 and a downward trend starting in 2019. Patients from the general population, centers for addictions, and prison differed significantly. The mean age in the general population remained above 60 years, the percentage of patients from centers for addictions and prison increased and, after 2016, there was no significant change in the percentage of patients with F3-F4 fibrosis. As HCV screening and linkage-to-care pathways seem to be already well implemented and successful in centers for addictions and in prisons, efforts need to be focused on those of older age in the general population. To carry this out, the more structured involvement of different health professionals must be figured out.
丙型肝炎病毒（HCV）感染仍然是全球的一个主要负担，大多数国家都未能实现世界卫生组织（WHO）2030 年消除目标。目前的挑战是确定需要治疗的人群。在本研究中，我们将描述我们单位开始抗病毒治疗的患者特征方面，新直接抗病毒药物（DAA）处方数量的趋势和随时间的变化。分析了 2015 年至 2022 年期间接受治疗的 1646 例丙型肝炎患者的年度处方数量、年龄、性别、国籍、丙型肝炎病毒基因型、来源和肝病严重程度等数据。我们观察到 2018 年新处方数量达到峰值，2019 年开始呈下降趋势。一般人群、成瘾治疗中心和监狱的患者有显著差异。一般人群的平均年龄仍高于 60 岁，来自成瘾治疗中心和监狱的患者比例增加，并且自 2016 年以来，F3-F4 纤维化患者的比例没有明显变化。由于丙型肝炎病毒的筛查和治疗衔接途径似乎已经在成瘾治疗中心和监狱中得到很好的实施和成功，因此需要将重点放在一般人群中年龄较大的人群上。为了实现这一目标，必须明确不同卫生专业人员更有组织的参与。
